With an estimated 1.6 million deaths worldwide annually, lung cancer is the leading cause of cancer death. However, progress is being made in improving the prevention, diagnosis and treatment of this malignancy. At the European Cancer Congress in Vienna, a substantial number of presentations reported encouraging results of early and late phase clinical trials in lung cancer. Below an impression of several of these studies.
(BELG J MED ONCOL 2015;9(:206–11)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
